Skip Navigation


Rheumatology Advance Access originally published online on July 31, 2006
Rheumatology 2006 45(9):1058-1061; doi:10.1093/rheumatology/kel230
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
45/9/1058    most recent
kel230v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Morrison, E.
Right arrow Articles by Capell, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morrison, E.
Right arrow Articles by Capell, H. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

EDITORIAL

Corticosteroids in the management of early and established rheumatoid disease

E. Morrison1, and H. A. Capell2

1Department of Rheumatology, Southern General Hospital and 2Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Scotland, UK

Correspondence to: Dr Elaine Morrison, Consultant Physician & Rheumatologist, Southern General Hospital, 1345 Govan Road, Glasgow G51 4TF. E-mail: elaine.morrison@sgh.scot.nhs.uk

The first 150 words of the full text of this article appear below.

Corticosteroid use in rheumatoid arthritis (RA) remains something of a dichotomy to most rheumatologists. How do we reconcile the promise of disease-modifying activity in early disease with the possibility of significant and potentially long-lasting adverse effects? Is the benefit of the former sufficiently marked to justify the latter? In addition, since the debate concerning corticosteroid use in RA was re-ignited some years ago, ideas about the management of RA have moved on. More intense use of disease-modifying anti-rheumatic drugs (DMARDs), either singly or in combination, and the proliferation of anti-tumour necrosis factor (TNF-{alpha}) agents have had an enormous impact on how we now manage RA [1, 2]. Where do corticosteroids fit into our current treatment strategies?

RA has also emerged as an independent risk factor for atherosclerosis over and above those more traditionally recognised (e.g. hypertension, diabetes mellitus, weight and lipid profile) as a link between . . . [Full Text of this Article]

Corticosteroid use in early RA

Efficacy

Toxicity

Corticosteroid use in established RA

Does route of administration of corticosteroids matter?

Corticosteroids and cardiovascular risk

Summary


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
N. Iikuni, E. Inoue, E. Tanaka, M. Hara, T. Tomatsu, N. Kamatani, and H. Yamanaka
Low disease activity state with corticosteroid may not represent 'true' low disease activity state in patients with rheumatoid arthritis
Rheumatology, April 1, 2008; 47(4): 519 - 521.
[Abstract] [Full Text] [PDF]